Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the Carcinoid Tumor Market from 2024 to 2025?
Recently, there has been a quick expansion in the size of the carcinoid tumor market. Projected growth indicates an increase from $1.61 billion in 2024 to $1.78 billion in 2025, with a 10.7% compound annual growth rate (CAGR). Factors contributing to this historic growth include a higher number of neuroendocrine tumor cases, increased awareness about uncommon types of cancer, enhanced healthcare facilities, the accessibility of target-specific therapies, and the widening scope of clinical trials for novel treatment opportunities.
What Is the Projected Market Size of the Carcinoid Tumor Market?
In the forthcoming years, the market size for carcinoid tumors is anticipated to undergo swift expansion, reaching a valuation of $2.65 billion by 2029 with a Compound Annual Growth Rate (CAGR) of 10.5%. Factors such as the escalating need for personalized medication, amplified emphasis on early detection and diagnosis, a higher inclination towards minimally invasive surgical procedures, widened research on pioneering therapies, and the heightened application of molecular targeted treatments contribute to the anticipated growth in this period. Further, the approaching years will see a rise in trends like the inclusion of AI and machine learning in diagnostic practices, a pivot towards combined therapies, the adoption of telemedicine and remote monitoring, a focus on patient-centric health care, and cooperative research.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21127&type=smp
Who are the Major Competitors in the Carcinoid Tumor Market Outlook?
Major companies operating in the carcinoid tumor market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Sanofi S.A., Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Siemens Healthineers AG, Boston Scientific Corporation, Boehringer Ingelheim International GmbH, Catalent Inc, Ipsen S.A., Exelixis Inc, Novocure Limited, Hutchison MediPharma Limited (A subsidiary of HUTCHMED), Tarveda Therapeutics Inc., Lexicon Pharmaceuticals Inc., Dauntless Pharmaceuticals Inc.
What Is Fueling Growth in the Carcinoid Tumor Market?
The rise in the number of obese individuals is predicted to drive the expansion of the carcinoid tumor market. These individuals are defined as those with a body mass index (BMI) over 30, which signifies an excessive accumulation of body fat. The increase in obesity is linked to unhealthy eating patterns, absence of regular exercise, inactive lifestyles, and the higher consumption of processed foods rich in calories. Obesity plays a role in the formation of carcinoid tumors by triggering chronic inflammation, resistant insulin, and the overproduction of growth factors that aid in tumor growth. To illustrate, the Centers for Disease Control and Prevention, a government agency in the US, reported in September 2023 that in 2022, the adult obesity rate reached or exceeded 35% in 22 states, an increase from 19 states in 2021. Consequently, the escalating obesity rates are propelling the development of the carcinoid tumor market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=21127&type=smp
Which Carcinoid Tumor Market Segments Are Growing the Fastest?
The carcinoid tumor market covered in this report is segmented –
1) By Disease Type: Gastrointestinal Neuroendocrine Tumor, Pancreatic Neuroendocrine Tumor, Lung Neuroendocrine Tumor, Other Disease Types
2) By Treatment: Octreotide, Lanreotide, Telotristat ethyl, Capecitabine (Xeloda), 5-Fluorouracil (5-FU), Doxorubicin (Adriamycin), Etoposide (VP-16), Dacarbazine (DTIC), Streptozocin, Other Treatments
3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
4) By Distribution Channel: Online Channel, Offline Channel
5) By End User: Hospital And Clinics, Academic Institutions, Research Organizations
Subsegments:
1) By Gastrointestinal Neuroendocrine Tumor: Small Bowel Neuroendocrine Tumors, Colorectal Neuroendocrine Tumors, Appendiceal Neuroendocrine Tumors
2) By Pancreatic Neuroendocrine Tumor: Insulinoma, Non-insulinoma, Glucagonoma
3) By Lung Neuroendocrine Tumor: Typical Carcinoid Tumors, Atypical Carcinoid Tumors
4) By Other Disease Types: Thymic Neuroendocrine Tumors, Ovarian Neuroendocrine Tumors
Which Industry Trends Are Shaping the Future of the Carcinoid Tumor Market?
Leading corporations in the carcinoid tumor industry are concentrating their efforts on improving diagnostic technologies. One such technology is the fully automated chromogranin A test, which can aid in early detection and improved treatment outcomes. The automated chromogranin A (CgA) test functions as a comprehensive diagnostic instrument that measures levels of chromogranin A, a biomarker frequently linked to neuroendocrine tumors and carcinoid tumors. An example of this is when, in October 2023, Thermo Fisher Scientific Inc., a US biotechnology research firm, secured FDA approval for its Thermo Scientific B·R·A·H·M·S CgA II KRYPTOR immunoassay. This established the first FDA-sanctioned Chromogranin A (CgA) test and the sole automated immunoassay internationally used for tracking tumor progression in gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients. The assay, designed to measure CgA concentration in human serum, equips labs and cancer centers with the capability to monitor tumor growth and evaluate treatment effectiveness. This replaces manual lab-developed tests, thereby enhancing laboratory productivity and offering more lucid result interpretation. This test operates on the Thermo Scientific B·R·A·H·M·S KRYPTOR compact PLUS random-access immunoassay analyzer, utilizing TRACE technology to provide accurate results in less than 30 minutes.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/carcinoid-tumor-global-market-report
Which Countries Are Leading the Carcinoid Tumor Market?
North America was the largest region in the carcinoid tumor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the carcinoid tumor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21127
This Report Delivers Insight On:
1. How big is the carcinoid tumor market, and how is it changing globally?
2. Who are the major companies in the carcinoid tumor market, and how are they performing?
3. What are the key opportunities and risks in the carcinoid tumor market right now?
4. Which products or customer segments are growing the most in the carcinoid tumor market?
5. What factors are helping or slowing down the growth of the carcinoid tumor market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model